(Press-News.org) Insect pupae hiss like snakes for defense. A Kobe University team now reveals the mechanisms, opening the door to further studies involving predator reactions to defensive sounds.
Just as you would shout or make noise to drive off a perceived threat, some insects have been known to produce defensive sounds. Some moths, for example, have been observed producing sounds to ward off predators at multiple developmental stages; pupal sound production has so far been attributed mainly to physical friction between body parts. “We became interested in this topic when we noticed that the larvae and pupae of a hawkmoth species produced surprisingly loud sounds when stimulated,” says Kobe University ecologist SUGIURA Shinji.
In order to explore how this works, Sugiura and his team examined how larvae and pupae of the buff-leaf hawkmoth (Phyllosphingia dissimilis) respond to being touched by forceps simulating an attack, like a bird peck or predator bite. The team recorded both body movement and sound production responses for each larva and pupa and also studied how the animals’ internal organs were involved in the sound production.
In the Journal of Experimental Biology, the team now reports that the majority of mature larvae and half of the pupae used in testing reacted to being touched, with both producing sounds and rapidly moving their bodies. Underwater testing then revealed that these sounds were being released through the animals’ respiratory openings, which were visible as air bubbles. Sugiura explains the significance of this finding: “Until now, pupal sound production was thought to occur only through physical friction between body parts or against the substrate. This is the first evidence demonstrating a sound production mechanism in pupae that is driven by forced air.”
But why would these insects use forced air to make these sounds in the first place? Sugiura goes on to provide a scaly suggestion: “Both the larvae and pupae of this species produce similar acoustic patterns. Their hissing air sounds resemble the warning sounds made by snakes. Because hawkmoth larvae and pupae are likely preyed upon by birds and small mammals — animals that may themselves be attacked by snakes — we hypothesize that this hawkmoth species acoustically mimics snake warning signals to protect itself.”
Further research could open the door to investigating whether similar mechanisms occur in other taxa and examine the behavior of potential predators when exposed to these defensive sounds.
This research was funded by the Japan Society for the Promotion of Science (grant JP17K08158). It was conducted in collaboration with researchers from the Forestry and Forest Products Research Institute.
Kobe University is a national university with roots dating back to the Kobe Higher Commercial School founded in 1902. It is now one of Japan’s leading comprehensive research universities with over 16,000 students and over 1,700 faculty in 11 faculties and schools and 15 graduate schools. Combining the social and natural sciences to cultivate leaders with an interdisciplinary perspective, Kobe University creates knowledge and fosters innovation to address society’s challenges.
END
A sound defense: Noisy pupae puff away potential predators
2025-12-07
ELSE PRESS RELEASES FROM THIS DATE:
Azacitidine–venetoclax combination outperforms standard care in acute myeloid leukemia patients eligible for intensive chemotherapy
2025-12-07
(ORLANDO, Dec. 7, 2025) In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction chemotherapy. The azacitidine–venetoclax combination (known as aza-ven) is the standard of care for older adults who are not fit enough for intensive chemotherapy. The trial is the first to test the superiority of this regimen to intensive induction chemotherapy, the current standard for fit patients.
“Our study met ...
Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes
2025-12-07
(ORLANDO, Dec. 7, 2025) In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab in addition to the standard second-line regimen versus the standard regimen alone. The study is the first reported randomized controlled trial to test a bispecific antibody combination in follicular lymphoma and suggests the combination could offer an effective alternative to chemotherapy that can be safely administered on an outpatient basis.
Based on the study results, the U.S. Food and Drug Administration (FDA) approved epcoritamab with ...
New findings support a chemo-free approach for treating Ph+ ALL
2025-12-07
(ORLANDO, Dec. 7, 2025) A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic leukemia (ALL) in a new study. The phase III trial, which included adult patients with no upper age limit, is the first formal comparison of the efficacy and safety of these two approaches in newly diagnosed patients with Ph+ ALL.
Researchers say the findings offer reassurance that chemotherapy can be omitted without detrimental effects and suggest that a chemo-free targeted agent and immunotherapy combination could become the new standard of care for this patient group.
“The chemo-free approach ...
Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL
2025-12-07
(ORLANDO, Dec. 7, 2025) Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib, a covalent BTK inhibitor. Based on the study results, researchers suggest pirtobrutinib shows promise as initial BTK inhibitor therapy, including in the frontline setting, for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Non-covalent BTK inhibitors were initially developed to overcome resistance to covalent ...
University of Cincinnati experts present research at annual hematology event
2025-12-06
University of Cincinnati researchers will present research at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition Dec. 6 to 9 in Orlando.
Phase 1 data testing new CLL treatment encouraging
A class of drugs called BTK inhibitors have become a standard treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). However, the prevalence of new resistance mutations has created a need for new treatments in patients with relapsed CLL who progressed through approved standard of care options, said the Cancer Center’s Zulfa Omer, MD.
“This is an area of unmet need, with current options providing ...
ASH 2025: Antibody therapy eradicates traces of multiple myeloma in preliminary trial
2025-12-06
MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 6, 2025, AT 2:00 P.M. EST) – Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine. The findings will be presented Dec. 6, 2025, at the American Society of Hematology (ASH) annual meeting in Orlando.
None of the 18 patients who completed up to six cycles of treatment with the antibody linvoseltamab had detectable disease on highly sensitive tests. This preliminary ...
ASH 2025: AI uncovers how DNA architecture failures trigger blood cancer
2025-12-06
Article Summary:
Researchers found that DNA’s shape matters. When its loops break, cancer can start.
Based on a new concept of architectural tumor suppression, researchers used proteins that organize DNA to also help prevent lymphoma.
Artificial intelligence helped reveal the changes that could guide future treatments.
MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 6, 2025, AT 9:50 A.M. EST) – Cancer isn’t just about broken genes—it’s about broken architecture. Imagine a city where roads suddenly vanish, ...
ASH 2025: New study shows that patients can safely receive stem cell transplants from mismatched, unrelated donors
2025-12-06
Article Summary
ACCESS study reveals patients can safely receive stem cell transplants from unrelated donors with multiple genetic mismatches.
A protective regimen acts as a “bridge,” preventing complications and boosting survival rates.
Findings could make transplants accessible to nearly all patients with blood cancers, regardless of ancestry.
Study will be presented at ASH Dec. 8 and will also be highlighted in a special ASH press briefing Dec. 6 at 8:30AM EST.
MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 6, 2025, AT 8:30AM) – For years, the ...
Protective regimen allows successful stem cell transplant even without close genetic match between donor and recipient
2025-12-06
(ORLANDO, Dec. 6, 2025) A new study shows that giving the chemotherapy drug cyclophosphamide after allogeneic hematopoietic cell transplantation, a curative treatment for common types of blood cancer, can make the procedure safe and effective even when donors and recipients are unrelated and have extensive genetic mismatches. Historically, genetic compatibility has played a primary role in identifying matched donors; these results suggest that many patients who need a transplant could now have access to a much broader pool of potential donors and expect outcomes comparable to those from fully matched donors.
The study found that one-year survival was similar whether patients received ...
Continuous and fixed-duration treatments result in similar outcomes for CLL
2025-12-06
(ORLANDO, Dec. 6, 2025) According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed period of time.
The study is the first prospective trial to directly compare these two approaches. With a median follow-up of nearly three years, the results show these approaches are essentially equivalent in terms of risk of death or disease progression.
“As clinicians, we often assume ...